Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
JNNP 35:385, Patten,B.M.,et al, 1972
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017
Oral Versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients with Multiple Sclerosis (COPOUSEP):A Randomised, Controlled, Double-Blind,Non-Inferiority Trial
Lancet 386:974-981, LePage,E.,et al, 2015
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Clinical and MRI Outcome after Autologous Hematoipoietic Stem Cell Transplantation in MS
Neurol 62:282-284,168, Saiz,A.,et al, 2004
European Study on Intravenous Immunoglobulin in Multiple Sclerosis
Arch Neurol 61:1409-1412, Filippi,M.,et al, 2004
Intravenous Immunoglobulin Treatment Following the First Demyelinating Event Suggestive of Multiple Sclerosis
Archn Neurol 61:1515-1520, Achiron,A.,et al, 2004
Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis: Randomised Placebo-Controlled Trial
Lancet 364:1149-1156, Hommes,O.R.,et al, 2004
IV Immunoglobulins as Add-on Treatment to Methylprednisolone for Acute Relapses in MS
Neurol 63:2028-2033, Sorensen,P.S.,et al, 2004
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Plasma Exchange for Severe Attacks of CNS: Demyelination: Predictors of Response
Neurol 58:143-146, Keegan,M.,et al, 2002
Differentiation of Multiple Sclerosis from Other Inflammatory Disorders and Cerebrovascular Disease: Value of Spinal MR Imaging
Radiology 223:46-56, Bot,J.C.J.,et al, 2002
Autologous Hematopoietic Stem Cell Transplantation Suppresses Gd-enhanced MRI activity in MS
Neurol 57:62-68, Mancardi,G.L.,et al, 2001
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Association of MS with Thyroid Disorders
Neurol 53:883-885, Karni,A.&Abramsky,O., 1999
Intravenous Immunoglobulin Treatment in Multiple Sclerosis, Effect on Relapses
Neurol 50:398-402, Achiron,A.,et al, 1998
Optic Neuritis, Prognosis for Multiple Sclerosis from MRI, CSF, and HLA Findings
Neurol 50:708-714, Soderstrom,M.,et al, 1998
Intravenous Immunoglobulin G Reduces MRI Activity in Relapsing Multiple Sclerosis
Neurol 50:1273-1281, Sorensen,P.S.,et al, 1998
The Predictive Value of CSF Ologoclonal Banding for MS 5 Years After Optic Neuritis
Neurol 51:885-887, Cole,S.R.,et al, 1998
Randomised Placebo-Controlled Trial of Monthly IVIg Therapy in Relapsing-Remitting MS
Lancet 349:589-593, 5861997., Fazekas,F.,et al, 1997
Correlation of Clinical, Magnetic Resonance Imaging, and Cerebrospinal Fluid Findings in Optic Neuritis
Ann Neurol 41:392-398, Jacobs,L.D.,et al, 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Antiphospholipid Antibody Syndrome Mimicking Multiple Sclerosis Clinically and by Magnetic Resonance Imaging
Arch Int Med 154:917-920, Scott,T.F.,et al, 1994
A Patient with Primary Biliary Cirrhosis and Multiple Sclerosis
Am J Med 92:433-436, Pontecorvo,M.J.,et al, 1992
Open Controlled Therapeutic Trial of Intravenous Immune Globulin in Relapsing-Remitting Multiple Sclerosis
Arch Neurol 49:1233-1236, Achiron,A.,et al, 1992
Cerebrospinal Fluid Immunoglogulins & MS, Correspondence MRI & Visually Evoked Potential Changes
Arch Neurol 46:367-371, Miller,F.A.J.,et al, 1989
Autoimmunity in Multiple Sclerosis
Neurol 38:371-374, DeKeyser,J., 1988
Immunologic Aspects of Neurological & Neuromuscular Diseases
JAMA 258:2970-2973, Zweiman,B.&Arnason,B.G.W., 1987
The Relationship Between Levels of CSF Myelin Basic Protein & IgG Measurements in Patients with Multiple Sclerosis
Ann Neurol 17:475-480, Warren,K.G.,et al, 1985
Multiple Sclerosis & Autoimmune Diseases
Neurol 33:97-98, Lo,R.,et al, 1983
New Diagnostic Criteria for Multiple Sclerosis:Guidelines for Research Protocols
Neurol 13:227-231, Poser,C.M.,et al, 1983
Correlation of Isotopic Cisternographic Patterns in Multiple Sclerosis with CSF IgG Values
Ann Neurol 12:486-489, Bartolini,S.,et al, 1982
The Use & Abuse of the Cerebrospinal Fluid IgG Profile in the Adult:A Practical Evaluation
Ann Neurol 8:426-434, Hershey,L.A.,et al, 1980
Multiple Sclerosis de Novo CNS IgG Synthesis:Effect of ACTH & Corticosteroids
Neurol 30:1155-1162, Tourtellotte,W.W.,et al, 1980
Cerebrospinal Fluid IgG, IgA, IgM, IgD, & IgE Levels in Central Nervous System Disorders
Neurol 28:988-990, Nerenberg,S.T.,et al, 1978
Antibodies to Oligodendroglia in Patient with Multiple Sclerosis
NEJM 297:1207, Abramsky,O.,et al, 1977